Eligibility Details:
Inclusion Criteria:
1. At least 18 years old.
2. Presence of a DFU extending at least through the dermis but not into tendon, muscle,
or bone, provided it is below the medial aspect of the malleolus (UT grade IA/IC; see
Appendix A for definitions).
3. The index ulcer will be the largest ulcer if two or more eligible DFUs are present and
will be the only one evaluated in the study. If other ulcerations are present on the
same foot, they must be more than 2 cm distant from the index ulcer.
4. Index ulcer (i.e. current episode of ulceration) has been present for greater than 4
weeks prior to SV1 and less than 1 year, as of the date the subject consents for
study.
5. Index ulcer is a minimum of 1.0 cm2 and a maximum of 25 cm2 at SV1 and TV1.
6. Adequate circulation to the affected foot as documented by a dorsal transcutaneous
oxygen measurement (TCOM) or a skin perfusion pressure (SPP) measurement of ≥ 30 mmHg,
or an ankle brachial index (ABI) between 0.7 and 1.1 within 3 months of SV1, using the
affected study extremity. As an alternative, arterial Doppler ultrasound can be
performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the
level of the ankle, or a toe brachial index (TBI) of > 0.6 is acceptable.
7. The target ulcer has been offloaded for at least 14 days prior to randomization.
8. Females of childbearing potential must be willing to use acceptable methods of
contraception (birth control pills, barriers or abstinence) during the course of the
study and undergo pregnancy tests.
9. Subject understands and is willing to participate in the clinical study and can comply
with weekly visits
Exclusion Criteria:
1. Index ulcer(s) deemed by the investigator to be caused by a medical condition other
than diabetes.
2. Index ulcer, in the opinion of the investigator, is suspicious for cancer and should
undergo an ulcer biopsy to rule out a carcinoma of the ulcer.
3. Index ulcer on the heel
4. Subjects with a history of more than two weeks treatment with immunosuppressants
(including systemic corticosteroids >10mg daily dose), cytotoxic chemotherapy, or
application of topical steroids to the ulcer surface within 1-month prior to first
SV1, or who receive such medications during the screening period or who are
anticipated to require such medications during the course of the study.
5. Subjects on any investigational drug(s) or therapeutic device(s) within 30 days
preceding SV1.
6. Subjects who have received a biomedical or topical growth factor for their wound
within the previous 30 days.
7. History of radiation at the ulcer site (regardless of time since last radiation
treatment).
8. Index ulcer has been previously treated or will need to be treated with any prohibited
therapies. (See Section 7.3 of this protocol for a list of prohibited medications and
therapies).
9. Subject has a known history of poor adherence with medical treatment.
10. Osteomyelitis or bone infection of the affected foot as verified by x-ray within 30
days prior to randomization. (In the event of an ambiguous diagnosis, the Principal
Investigator will make the final decision).
11. Subject is pregnant or breast-feeding.
12. Presence of diabetes with poor metabolic control as documented with an HbA1c >12.0
within 90 days of randomization.
13. Subjects with end stage renal disease as evidenced by a serum creatinine ≥ 3.0 mg/dL
within 6 months of randomization.
14. Index ulcer has reduced in area by 20% or more after 14 days of SOC from SV1 to the
TV1/randomization visit.